LakeShore Biopharma (LSB) has received a written notice from the Nasdaq Listing Qualifications Department informing the company that it has regained compliance with the minimum bid price requirement. According to the compliance notice, the company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the company’s ordinary shares have been $1.00 per share or greater for 11 consecutive business days, from October 4 to October 18, and the matter is now closed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSB:
- LakeShore Biopharma Advances with Rabies Vaccine Trial
- LakeShore’s YSJA rabies vaccine receives approval for Phase III trial in China
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz
- LakeShore Biopharma Projects Strong Growth in 2025
- LakeShore Biopharma still sees FY25 revenue up in double digits year-over-year